BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 45 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2019. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $45,000 | +18.4% | 11,800 | +18.0% | 0.00% | 0.0% |
| Q1 2021 | $38,000 | +216.7% | 10,000 | +1328.6% | 0.00% | 0.0% |
| Q3 2020 | $12,000 | +500.0% | 700 | +40.0% | 0.00% | – |
| Q1 2020 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q4 2019 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q3 2019 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q2 2019 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q1 2019 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q4 2018 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q3 2018 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q2 2018 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q1 2018 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q4 2017 | $2,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q3 2017 | $2,000 | -33.3% | 500 | -24.9% | 0.00% | – |
| Q1 2017 | $3,000 | – | 666 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |